S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12

Caribou Biosciences Stock Forecast, Price & News

-1.66 (-8.93%)
(As of 12/1/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
503,157 shs
Average Volume
669,524 shs
Market Capitalization
$1.02 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CRBU News and Ratings via Email

Sign-up to receive the latest news and ratings for Caribou Biosciences and its competitors with MarketBeat's FREE daily newsletter.

About Caribou Biosciences

Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in BERKELEY, Calif.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales


Pretax Margin




Free Float
Market Cap
$1.02 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.98 out of 5 stars

Medical Sector

645th out of 1,392 stocks

Biological Products, Except Diagnostic Industry

99th out of 202 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Caribou Biosciences (NASDAQ:CRBU) Frequently Asked Questions

Is Caribou Biosciences a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Caribou Biosciences in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Caribou Biosciences stock.
View analyst ratings for Caribou Biosciences
or view top-rated stocks.

Are investors shorting Caribou Biosciences?

Caribou Biosciences saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 1,540,000 shares, an increase of 32.8% from the October 31st total of 1,160,000 shares. Based on an average trading volume of 577,300 shares, the short-interest ratio is presently 2.7 days. Approximately 3.3% of the company's stock are sold short.
View Caribou Biosciences' Short Interest

When is Caribou Biosciences' next earnings date?

Caribou Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, February 8th 2022.
View our earnings forecast for Caribou Biosciences

How were Caribou Biosciences' earnings last quarter?

Caribou Biosciences, Inc. (NASDAQ:CRBU) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.34. The company earned $3.98 million during the quarter, compared to analyst estimates of $3 million.
View Caribou Biosciences' earnings history

What price target have analysts set for CRBU?

5 brokers have issued 12-month price targets for Caribou Biosciences' stock. Their forecasts range from $27.00 to $36.00. On average, they anticipate Caribou Biosciences' stock price to reach $30.60 in the next twelve months. This suggests a possible upside of 80.7% from the stock's current price.
View analysts' price targets for Caribou Biosciences
or view top-rated stocks among Wall Street analysts.

When did Caribou Biosciences IPO?

(CRBU) raised $202 million in an initial public offering on Friday, July 23rd 2021. The company issued 13,500,000 shares at $14.00-$16.00 per share.

What is Caribou Biosciences' stock symbol?

Caribou Biosciences trades on the NASDAQ under the ticker symbol "CRBU."

When does the company's lock-up period expire?

Caribou Biosciences' lock-up period expires on Wednesday, January 19th. Caribou Biosciences had issued 19,000,000 shares in its public offering on July 23rd. The total size of the offering was $304,000,000 based on an initial share price of $16.00. After the expiration of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Who are Caribou Biosciences' major shareholders?

Caribou Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Farallon Capital Management LLC (4.92%), Janus Henderson Group PLC (2.06%), BlackRock Inc. (1.97%), Maverick Capital Ltd. (1.58%), FIL Ltd (1.43%) and Coatue Management LLC (1.17%). Company insiders that own Caribou Biosciences stock include Barbara G Mcclung, Ryan Fischesser and Steven Kanner.
View institutional ownership trends for Caribou Biosciences

Which institutional investors are buying Caribou Biosciences stock?

CRBU stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Janus Henderson Group PLC, BlackRock Inc., Maverick Capital Ltd., FIL Ltd, Coatue Management LLC, 72 Investment Holdings LLC, and Monashee Investment Management LLC. Company insiders that have bought Caribou Biosciences stock in the last two years include Barbara G Mcclung, Ryan Fischesser, and Steven Kanner.
View insider buying and selling activity for Caribou Biosciences
or or view top insider-buying stocks.

How do I buy shares of Caribou Biosciences?

Shares of CRBU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Caribou Biosciences' stock price today?

One share of CRBU stock can currently be purchased for approximately $16.93.

How much money does Caribou Biosciences make?

Caribou Biosciences has a market capitalization of $1.02 billion.

How many employees does Caribou Biosciences have?

Caribou Biosciences employs 2,021 workers across the globe.

What is Caribou Biosciences' official website?

The official website for Caribou Biosciences is cariboubio.com.

How can I contact Caribou Biosciences?

The company can be reached via phone at 510-982-6030.

This page was last updated on 12/2/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.